Top Software Companies in Philadelphia, PA (267)

Strong Revenue Growth: Reported $100M in contracted annual recurring revenue by the end of 2025 and a high placement on Deloitte’s Technology Fast 500 together indicate substantial multi‑year expansion.

Investor Backing & Capital Strength: A $65M growth investment led by established firms signals strong access to capital and confidence in the company’s expansion plans.

Strong Market Position & Advantage: Recognition as #1 Best in KLAS for Patient Communications in 2026 and adoption across 1,000+ healthcare organizations reflect meaningful category standing.

Strong Revenue Growth: Recent results show total net revenue rising sharply—up 37% in 2025 and about 26% year over year in Q2 2026—while management described performance as reflecting solid top-line growth. Purchase volume also expanded materially, including a 27% increase in 2025 and strong gains into 2026.

Market Expansion: Scale expanded meaningfully with the May 2025 Discover acquisition, which added assets, deposits, loan portfolios, and payment-network capabilities. As of early 2026, reported assets of about $683 billion and deposits near $489 billion underscore the larger combined footprint, and external commentary anticipates further expansion.

Strong Market Position & Advantage: The company is identified as the largest U.S. credit-card issuer by outstanding balances as of year-end 2025 and one of the nation’s largest banks by deposits, with customer-satisfaction leadership among national banks. The addition of Discover’s network further reinforces a differentiated competitive position.

Strong Revenue Growth: Recent quarters show record revenue with both net interest income and fee income increasing. Capital-markets and advisory income also strengthened, contributing to broad-based top-line momentum.

Profitability: Net income has risen materially year over year alongside positive operating leverage. Management commentary highlights higher earnings power, reflected in stronger quarterly results and upgraded outlook items.

Market Expansion: The acquisition of FirstBank expanded the franchise in Colorado and Arizona and added loans, deposits, and assets. Plans to open more than 300 new branches by 2030 and related hiring signal an active push into new and existing markets.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Investor Backing & Capital Strength: Funding progression includes a reported Series A in 2023 and total capital in the mid‑teens of millions, indicating resources to scale operations and product. Named institutional investors and multiple rounds point to continued capacity to support growth initiatives.

Market Expansion: Positioning has broadened from forestry robotics into AI‑powered field operations for utilities, including vegetation management, asset inspection, construction, and disaster response. This shift suggests access to larger, higher‑value commercial segments.

Product Line Growth: Activity logs cite next‑generation backpack and vehicle hardware shipments, faster data processing, expanded species identification, and a desktop review application. These updates indicate ongoing investment in capabilities aligned to real‑world utility workflows.

Strong Revenue Growth: Disclosures indicate revenue roughly doubled since 2020 with guidance near $1.2–$1.25 billion for 2025, pointing to sustained top-line expansion. Announcements attribute this to strong organic momentum alongside margin expansion.

Investor Backing & Capital Strength: A definitive agreement to be acquired by Thermo Fisher Scientific for about $8.9 billion, with potential performance-based payments, signals substantial external validation and financial support. Deal materials highlight expected accretion and synergy potential.

Innovation-Driven Growth: The company reports implementing over 30 AI solutions, with more than half active across platforms, to transform endpoint analyses. Recent AI-focused certifications and technology investments underscore a scaled commitment to innovation.

Profitability: Recent results indicate growing revenue alongside strong margins and cash generation, with management emphasizing disciplined spending and operating leverage. This financial profile points to durable earnings power that can support reinvestment and shareholder returns.

Innovation-Driven Growth: Ongoing launches such as employee-driven payroll and an AI engine are highlighted as improving accuracy, reducing manual effort, and increasing adoption and retention. Recognition for innovation and expanding usage of these tools suggests product momentum that supports long-term growth.

Market Expansion: The company has extended offerings into additional countries, added sales offices, and is moving upmarket with larger customers. These steps increase its addressable market and create multiple avenues for future revenue.

Resilient & Sustainable Growth: Forward visibility looks durable due to a $100+ billion companywide backlog and repeated references to multi‑year contract wins that extend revenue coverage into 2026. The outlook frames demand as supported by defense and federal IT modernization priorities, suggesting the business can absorb near-term volatility.

Strong Market Position & Advantage: GDIT is positioned as a top-tier federal IT prime, reinforced by recurring placement in major federal contractor rankings and a steady cadence of marquee awards across DoD, intel, and civilian agencies. Its scale inside General Dynamics and ability to deliver mission-critical programs (e.g., enterprise IT modernization and large federal systems) signal competitive advantage in accreditation-heavy government work.

Diversified Revenue Streams: Revenue support is described as coming from multiple General Dynamics segments (Aerospace, Marine, Combat Systems, Technologies) alongside GDIT’s mix of defense, intelligence, health, and civilian programs. This multi-segment and multi-mission exposure reduces dependence on any single program area and supports stability through procurement cycles.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across recent quarters and the latest fiscal year, with momentum reflected in higher quarterly results and a raised full‑year outlook. Near‑term guidance also points to continued expansion through the remainder of the year.

Profitability: Profitability has expanded alongside growth, with operating income and earnings increasing meaningfully in the latest quarter. A subscription‑heavy mix and higher full‑year operating income guidance support margin durability.

Strong Market Position & Advantage: Position in life‑sciences CRM remains dominant, with a very large share of biopharma seats cited by management and many top‑20 pharmas live on next‑gen Vault CRM. Broad adoption across Development and Quality Clouds and continued big‑pharma commitments reinforce competitive advantage.

Investor Backing & Capital Strength: Recent funding includes a $75 million Series C at a reported $1.3 billion valuation, following a prior Series B. Capital inflows are described as enabling enterprise go-to-market scale and new product rollout.

Strong Market Position & Advantage: Usage is reported in the millions across hundreds of thousands of organizations, including broad penetration within large enterprises. Consistent positioning as a category leader in automated process documentation supports a durable advantage.

Cost & Operational Efficiency: The company is described as unusually capital efficient, with minimal drawdown of prior funding. Efficiency claims coexist with rapid scaling of users and customers.

Investor Backing & Capital Strength: A recent majority investment by a private equity sponsor is positioned to accelerate growth and provides capital for continued product and M&A activity. This backing signals confidence in the company’s long-term scale-up plan.

Innovation-Driven Growth: The company has launched new suites and AI-driven capabilities across compliance and decisioning, indicating ongoing R&D investment. This cadence points to a roadmap focused on modernizing GTN and market-access operations.

Strong Market Position & Advantage: It is widely regarded as a specialized leader in pharma net revenue and market access operations with an end-to-end platform. Scale claims and broad manufacturer adoption signals support this positioning, even if many are self-reported.

Strong Market Position & Advantage: Independent analyst frameworks (e.g., Gartner MQ 2024–2026 and Forrester 2024 Wave) consistently place Cvent among Leaders with broad enterprise adoption and presence on buyer grids. Coverage highlights end-to-end breadth and a large supplier network that competitors often lack.

Investor Backing & Capital Strength: The 2023 go-private transaction with Blackstone is described as strengthening the balance sheet and investment capacity. Ownership under Blackstone is linked to continued R&D momentum and M&A firepower.

Product Line Growth: Multiple acquisitions since 2024 (e.g., Jifflenow, iCapture, Reposite, Splash, Goldcast, Prismm, and ON24) broaden capabilities from event operations into webinars and digital engagement. The company has also been shipping AI-enabled features across its event and hospitality clouds.